Drug Pricing Transparency and Accountability Act

Summary

Drug Pricing Transparency and Accountability Act This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 9 January 2023

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

2. 9 January 2023

   Introduced

   Introduced in House

   Source: IntroReferral

3. 9 January 2023

   Introduced

   Introduced in House

   Source: IntroReferral

4. 20 January 2023

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

5. 17 December 2024

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 9 January 2023 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 9 January 2023

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 9 January 2023

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 9 January 2023

  Open at official source

Sponsors

• Matthew Rosendale · R · Sponsor
• · hswm00 · Standing
• · hsif00 · Standing

Related records

• related to ← Drug Pricing Transparency and Accountability Act